Brought to you by 
Two years after it was founded, Padlock acquired by BMS for up to $600mm
08 Sep 2020
Executive Summary
Bristol-Myers Squibb Co. acquired autoimmune disease start-up Padlock Therapeutics Inc. for up to $225mm in up-front and near-term contingent milestones. Padlock could also receive $375mm in development and regulatory earn-outs.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Two years after it was founded, Padlock acquired by BMS for up to $600mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice